Clinical trial
Oral Immunotherapy for Children With Peanut Allergy: A Randomized Controlled Trial
NCT07895095 is registered in ClinicalTrials.gov with Laura Ozer Kettner as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Oral Immunotherapy for Children With Peanut Allergy: A Randomized Controlled Trial
- Lead sponsor
- Laura Ozer Kettner
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- October 31, 2031
- Enrollment
- 56 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
food allergies, food allergy in children, food allergy peanut, peanut allergic subjects, peanut allergies, peanut hypersensitivity
Arms
As registered; 2 arms.
-
Oral immunotherapy
Children randomized to oral immunotherapy will ingest a daily dose of peanut. Dose escalation will be performed approximately every two weeks at the allergy clinic or via online consultations. After approximately 6 months, a maintenance dose of 300 mg food protein will be reached and continued daily for 6-12 months.
-
Avoidance
Children randomized to avoidance will receive standard care for peanut allergy, namely avoidance of peanut.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Tolerance to peanut (4000 mg)
Proportion of children who tolerate a cumulative dose of 4000 mg of peanut protein at an oral food challenge
Lead sponsor's other trials
Laura Ozer Kettner, most recent start first.
Similar trials
Same condition (Peanut Hypersensitivity) and phase, most recent start first.
+24 more trials See the condition page